Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Citius OncologyCTOR +9.01%10 3-Year Book Growth Rate is 1.80% as of Jun. 2026, which is at its 10-year median of 1.80. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 910 Drug Manufacturers companies, Citius Oncology ranks worse than 60.88% on this metric.
During the past 12 months, Citius Oncology's average Book Value per Share Growth Rate was -15.70% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 1.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 4 years, the highest 3-Year average Book Value per Share Growth Rate of Citius Oncology was 1.80% per year. The lowest was 1.80% per year. And the median was 1.80% per year.
Citius Oncology (NAS:CTOR) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Citius Oncology 3-Year Book Growth Rate Related Terms
CTOR vs ZYBT, INCR, TLPH: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Citius Oncology's 3-Year Book Growth Rate falls into.
Citius Oncology 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 1.80% mean?
Citius Oncology (CTOR) has a 3-Year Book Growth Rate of 1.80% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Citius Oncology and its competitors. This is near median its historical median of 1.80. Over the past decade, Citius Oncology's 3-Year Book Growth Rate has ranged from 1.80 to 1.80. According to the industry distribution chart, Citius Oncology ranks #554 out of 910 companies in the Drug Manufacturers industry, placing it in the top 60.9%.
Is Citius Oncology's 3-Year Book Growth Rate too high?
Citius Oncology's current 3-Year Book Growth Rate of 1.80% is near median its 10-year median of 1.80. Over the past 10 years, this metric has ranged from a low of 1.80 to a high of 1.80. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Citius Oncology's value of 1.80% is 60.9% below this industry median. Based on the distribution chart, Citius Oncology ranks #554 out of 910 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's 3-Year Book Growth Rate compare to ZYBT and INCR?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #554 out of 910 companies for 3-Year Book Growth Rate. This places Citius Oncology in the lower half of its industry. The industry median 3-Year Book Growth Rate is 4.60. Citius Oncology's value of 1.80% is 60.9% below this benchmark. Historically, Citius Oncology's own 3-Year Book Growth Rate has ranged from 1.80 to 1.80 over the past decade. While the company's 10-year median is 1.80 vs. the industry median of 4.60, Citius Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 910 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current 3-Year Book Growth Rate of 1.80% is 60.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Citius Oncology and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current 3-Year Book Growth Rate is 1.80%, which is near median its own 10-year median of 1.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current 3-Year Book Growth Rate of 1.80%. The current 3-Year Book Growth Rate is 1.80%, which is near median its 10-year median of 1.80 and 60.9% below the Drug Manufacturers industry median of 4.60. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Citius Oncology (CTOR), the current 3-Year Book Growth Rate is 1.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
